DAFTAR PUSTAKA
1. Libby P. Prevention and Treatment of Atherosclerosis in Harrison’s Principles of Internal Medicine, 16th Ed, Vol. II editor by:Kasper DL, et al, The McGraw-Hill Companies US ; 2005 : 1430 – 34 2. Boedhi-Darmojo. Epidemiology of atherosclerotic disease: special focus on
cardiovascular disease. Dalam: Tanuwidjojo S, Rifqi S.
Atherosclerosis from to clinical practice, Naskah lengkap CardiologyUpdate Semarang, 2003 :p1-12. 3. Genest J, Libby P. Clinical trials of drugs affecting lipid metabolism. In:Libby, Bonow, Mann, Zipes. Braunwald’s heart disease. Saunders Elsevier.2007 4. Corwin Elizabeth J.Buku saku patofisiologi:Sistim Kardiovaskuler, Edisi 1.Jakarta: EGC,2009.h.477. 5. Marks Dawn B , Marks Afian D, Smith Collen M. Biokimia Kedokteran dasar : sebuah pendekatan klinis , Edisi 1,Jakarta : EGC , 2000h. 51330. 6. Gajra B, Candlish JK, Saha N, Heng CK, Soemantri AG, Tay JSH. Influ enceofpolymorphism for apolipoprotein B (ins/del, Xbal, EcoRI) and apolipoprotein E on serum lipids and apolipoproteins in a javanese population Genetic Epi demiology 1994; 11:p19-27.
7. Katzung BG. Basic and clinical pharmacology. 10th ed. McGraw Hill Lange. 2007; p. 566-8 8. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statinassociatedmemory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003 Jul. 23(7):871 80.PMID:12885101 9. Anna Ulfa, Gejala awal dan deteksi dini penyakit jantung koroner, Artikel Ilmiah Pd- PERSI, Jakarta, 2000. 10. Navas-Necher EL, Colangelo L, Beam C, Greenland P, Risk factors for coronary heart disease in men 18 to 39 years of age, Ann Intern Med, 2001;134:433-439. 11. Jalowiec DA, Hill JA, Myocardial infarction in the young and in woman, Cardiovasc Clin, 1989; 20: 197-206 (Medline) 12. Hills L.D. and Braundwald; E : Coronary-artery spasm. N. Engl. J. Med.2001;299:695 13. Deitcher SR, Rodgers GM (2004). Thrombosis and antithrombotic therapy. In : Greer JP, Foerster J, Lukens JN, et al. Wintrobe`s Clinical Hematology. 11th ed. Lippincott Williams and Wilkins. USA 1714-18. 14. Rilan tono LI dkk.Buku ajar kardiologi.FKUI.Jakarta,2003: hal,159-165. 15. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent M, WilliamsR. Lipoprotein (a) interaction with lipid and nonlipid risk factors in earlyfamilial coronary artery diasease. AteriosclerosiThrombosis and Vascular Biology Journal 1997; 17:p2783-92.
16. Cheitlin MD, Sokolow M, McIlroy MB. Coronary Heart Disease. Dalam: Clinical Cardiology. ed-6. San Fransisco: a Lange medical book, 1993: p147 – 57 17. Neal Michael J At aglance farmakologi medis : obat penurun lipid, edisi kelima.Jakarta : EMS ,2005 h,47. 18. Trianti M, Xanthos T, Iacovidou N, et al. Relationship between individual cardiovascular risk factors and localization of coronary atherosclerotic lesions. Heart and Lung: The journal of acute and critical care [Internet]. 2010. [cited: 2012 Feb 20]. Available from: http://www.heartandlung.org/article/S0147-9563(10)00278-5/abstract 19. Robert
W.Disorders
of
Lipids
Metebolism.In
:
Larsen
et
al,(Eds).WilliamTexbookof Endocrinolog TenthEdition. Saunders,New York, 2003 : 1642-91 20. Applegate WB ,Basile JN ,Carey R, Dzau P,Egan BM,Falkner B et all.The Sevant Report of The Join Commite on Prevention, Evaluation and Treatment of High Blood Pressure . US Departemen t of Healt and Human Service . 2003 : 3 – 15. 21. Frank M. Sacks, M.D; Marc A Pfeffer, M.D, PhD, Lemuel A. Moye, M.D, PhD;Group, The effect of pravastatin on coronary events after myocardial 22. Jhon ME Adam. Dislipidemia dalam Buku Ajar Ilmu Penyakit Dalam edisi 4 editor oleh: Aru W.Sudoyo dkk. Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI, Jakarta ; 2006 : 1948- 54
23. National Cholesterol Education Program. 2002. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol 24. Fodor JG, Frohlich JJ, Genest JG, McPherson PR. Recommendations for the management and treatment of dyslipidemia. Medicine Journal 2000. 25. Sargowo D.Proses aterosklerosis sebagai penyebab penyakit jantung koroner: ditinjau dari konsep patologi molekular sebagai landasan teori.Majalah Kedokteran Indonesia1995; 45(5):311-15 26. Adriana Branchi, Anna Maria Fiorenza, Effects Atorvastatin 10 mg and Simvastatin 20 mg , Patients
Hypercholesterolemia, Italy ,
Internasional Journal of Internasional Medicine ,VOL. 62,p,408-415 27. Hiroshi Yoshida, MD, dkk ,Effects of Simvastatin 20 mg/d on Serum Lipid pada populasi Hyperlipidemic Dalam The Internasional Journal of Internasional Medicine, Japanese,2005 28. Answar BT.Dislipidemia sebagai factor resiko penyakit jantung koroner . FK USU.2004.1-10. 29. Answar Bahri T . Faktor resiko Penyakit Jantung Koroner , FK USU , 2004. h,9 30. Jennings
PE.
The
mechanism
of
diabetic
macroangiopathy.
Diabetographia. nternational Medical Publication 2003; 11: 4-6
31. Malloy
Mary
J,
Kane
John
P.Agen
yang
digunakan
dalam
hiperlipidemia. Dalam : Katzung Bertram . Farmakologi dasar dan Klinik . Edisi 8. Jakarta : Salemba Medika , 2002 .h.421 – 2 32. Hibert Timothy, Lifshitz MS. Lipids and Dyslipoproteinemia in In; Heny’s Clinical Diagnosa and Management by Laboratory Methods. 21 th ed. Sauders Elsevier , 2007: 201-17. 33. Suryonhudoyo
Purnomo.DasarMolekuler
Penyakit
Aterosklerosis
dalam Kapita selekta Ilmu Kedokteran Molekuler,Sagung Seto , Cetakan II , Jakarta ,2007:58 64 34. Ma J, Sehgal NL, Ayanian JZ, Stafford RS (2005) National Trends in Statin Use by Coronary Heart Disease Risk Category. PLoS Med 2(5): e123. doi:10.1371/journal.pmed.0020123 35. Anis,Waspada Ancaman penyakit tidak menular, Solusi Pencegahan dari Aspek
Perilaku & Lingkungan, PT Elex Media Komputindo,
Jakarta, 2006, 53-65 36. Newburger JW. Dislipidemia pada masa anak-anak dan remaja. Dalam:Fyler DC (ed) Nadas Pediatric cardiology. ed-4 (terjemahan). Boston: Hanley & Belfus Inc, 1992 :p 332 – 41 37. Adam John MF .Dislipidemia .Dalam : Sudoyo Aru W, Setiyohadi Bambang ,Alwi Idrus dkk ,Buku Ajar Ilmu Penyakit Dalam Jilid III, Edisi IV , Jakarta : FK – UI ,2006h 19926-28.
38. Yates A. John, Defranzo Ralph A. Kelaianan metabolisme .Dalam Stein Jay H. Paduan Klinik Ilmu Penyakit dalam . Edisi ketiga Jakarta : EGC , 2001.h.660 39. Goldberg J.Diabetik Dyslipidemia : Cause and Consequenses,,Clinical Review. The journal of clinical Endocrinologi & Metabolism 2001;86 (3) ; 965-71 40. Answar BT.Dislipidemia sebagai factor resiko penyakit jantung koroner . FK USU.2004.1-10. 41. Jawaharlal
W.B.
Senaratne
and
Green
FR.
Pathobiology
of
atherosclerosis in Oxford Textbook of Surgery, 2nd edition editor by: Peter J. Morris,William C. Wood. Oxford press ,US ; 2000 : Vol. 3 42. Atika
Walujani
M,
Perlu
program
penanggulangan
penyakit
kardiovaskuler, Kompas Cyber Media – IPTEK, 4 Juni 2002. 43. Mannering D, Bennet ED, Ward DE, Dawkins K, Valentine H, et al (1987). Accurate detection of triple vessel disease in patients with exercise induced ST segment depression after infarction. Br Heart J. 57 133-8 44. Suhartono T, Dislipidemia pada Diabetes Melitus, Dalam Diabetes Melitus ditinjau dari berbagai aspek penyakit dalam.2007 : 31-35. 45. Libby Peter,The phatogenesis of Atherosklerosis, in: Kasper Dennis L, Faud Anthony S, Longo dan L , et al. Harrisons principles of internal medicine.Sixteenth Edition, USA : Mc Graw Hill,2005 h, 1425-33.
46. Kurniasih Rita,Wijaya Andi,Kadar LDL- teroksidasi suatu petanda biokimiawi untuk menentukan resiko penyakit jantung koroner. Dalam : Donosepoetro
Marsetio,.Suhandi
Budhiarto,dkk.Forum
Disgnostik,Bandung : Laboratorium Klinik Prodia,2001.h.1-7 47. Carleton Ford Penny ,Boldt A Marjorie, Penyakit Aterosklerotik Koroner .Dalam : Price ASylvia , Wilson M Lorraine. Patofisiologi Konsep Klinis Proses-Proses Penyakit .Jakarta EGC , Jakarta , 2002 48. Yogiantoro M . Hipertensi esensial dalam Buku Ajar Ilmu Penyakit Dalam edisi 4 editor oleh: Aru W.Sudoyo dkk. Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI, Jakarta ; 2006 : 610-4 49. Achar SA, Kundu S, NorcrossWA. Diagnosis of acute coronary syndrome. AmFam Physician 2005; 72: 119-26 50. Tanuwidjojo S Recent developmentinpathogenesis ofatherosclerosis. Dalam: Tanuwidjojo S, Rifqi S.Atherosklerosis from theory to clinical practice, Naskah lengkap Cardiology Update, 2003 :p13-18. 51. Waspadji Sarwono .Penyakit kronik dan Pencegahan nya . Dalam Soegondo Sidartawan Suwondo Pradana,Subekti Imam.Edisi ke 6,Jakarta : FK UI ,2007 52. Mayes PA. Pengangkutan dan Penyimpanan Lipid. Dalam: Muray RK, Granner DK, Mayes PA, Rodwell VW. Biokimia Harper. ed-25 (terjemahan). Appleton & Lange, 2003:p 254-70. 53. Ross R. Arteriosclerosis, an Overview. Dalam: Haber E. Molecular Cardiovascular Medicine. New York: Scientific American, 1995:p11-5
54. Sutopo. Gambaran kadar kolesterol, trigliserida, LDL dan HDL pada anak dengan orang tua hiperlipidemia. Bagian Ilmu Kesehatan Anak FK UNDIP, Semarang, 1995 : p3-36. Tesis. 55. Sinha S, Sinha U, Mather R, Goldin J, Fonarow G et al. Estimation of left ventricular ejection fraction using a novel multiphase, dark–blood, breath–hold MR imaging technique. AJR 1997; 169: 101 – 112. 56. Achar SA, Kundu S, NorcrossWA. Diagnosis of acute coronary syndrome. AmFam Physician 2005; 72: 119-26 57. Valentin Fuster, R. Wayne Alexander, Robert A. O' Rourke (2004). Cardiac catheterization, cardiac angiography and coronary blood flow and pressure measurements. In Hurst's The Heart. 17 483-537 58. Abrams HL: Complication of coronary arteriography. In Abrams HL, editor: Angiography: vascular and interventional radiology, ed 3, Boston,2003, Little, Brown. 59. Bodhie Darmojo, R, Kris-Pranarka & Sutrisno, B, Survei penyakit jantung pada orang usia lanjut, Dalam : Bunga Rampai Karangan Ilmiah, Buku II, Kardiovaskular, 1994, 168179 60. Page C,Curtis M, Walker M, Hoffman B.Integrate Pharmacology 3rd ed. MosbyElsevier. 2006; p. 325 – 6 61. Angiografi koroner. Dokumentasi Catlab RSUP H.Adam Malik Medan bulan februari 2014. 62. Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol lowering and ezetimibe.N Engl J Med. 2008;358(14):1507–8.
63. Gotto AM, editor. Contemporery diagnosis and management of lipid disorders.
Pennsylvania,
USA:
Handbooks
in
Healthcare
Compnay;2001 64. Randomised trail of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383‐9. 65. Heart Protection Study Collaborative Group. Heart protection study of choleasterol lowering with simvastatin in20,536 high‐risk individuals: a randomized placebo‐controlled trial. Lancet 2002: 360:7‐22. 66. National Cholesterol Education Program. 2002. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). National Institutes of Health. 67. Takemoto M,Liao JK. Pleotropic Effects of Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors.Arterioscler Thromb Vasc Biol. 2001: 1712-1719 68. Alatas
H,Karyomanggolo,
dkk
Desain
penelitian.Dalam
:Sastroasmono S,Ismail S.Dasar dasar metodologi penelitian klinik Edisi 3,Sagung seto 2008:92-111 69. Lwanga SK,Lemeshow sample Size Determination in Health Studies A Practical Manual. World Health Organization ,Geneva,2009. 70. Dahlan M Sopiyudin, Statistik untuk kedokteran dan kesehatan ,Ed 5, Salemba Medika ,Jakarta,2012
71. Bonetti PO,Lerman LO,Napoli C,Lerman A, Statin Effects Beyond Lipid Lowering are they Clinically Relevant ?Eur Hear J 2003 : 24; 225-248 72. Khera A.Biomaker in Heart Diseases,In:Lemos JA (Ed) Biomakers in Heart
Disease
Blackwell
Publishing
;1st
Edition
,Massachussetts,2008p.161-180. 73. Faxon. D.P., Fuster, V., Libby, P., Beckman, J.A., Hiatt, W.R., Thompson, R.W., Topper, J.N., Annex, B.H., Rundback, J.H., Fabunmi, R.P., Robertson, R.M., and Loscalzo, J. 2004. Atherocslerotic Vascular Disease Conference. Circulation, 109 : 2617-25 74. Friday KE, Citkowitz E. Dysbetalipoproteinemia. Emedicine 2002;13.
